Micron Announces New Share Repurchase Program

During its May 21 Analyst and Investor event, Micron technology, Inc. (MU) announced that its Board of Directors authorized a new share repurchase program. The company will be able to purchase up to $10 billion of its outstanding common stock. In addition, Micron announced plans to return up to 50% of free cash flow to […]

Read more...

Avinger Receives FDA Clearance for Patheris Lumivascular Artherectomy System

Avinger, Inc. reported on May 23 that the company has received 510(k) clearance from the FDA for its next-generation Pantheris Lumivascular atherectomy system. Lumivascular is the only technology that combines both real-time intravascular imaging with catheters to treat peripheral artery disease (PAD). This is the first image-guided atherectomy device for the treatment of PAD. Sonal […]

Read more...

Published Study Supports Global Medical’s Expandable Lateral Technology

On May 15, Global Medical, Inc. (GMED) reported the results of a medical study that supported the benefits of the company’s Globus expandable lateral spacers. The study “Clinical and radiographic analysis of expandable versus static lateral lumbar interbody fusion devices with two-year follow-up” was published in the Journal of Spine Surgery. Dr. Joseph O’Brien, MD, […]

Read more...

Heartland Express Announces Share Repurchase Program

On May 11, Heartland Express, Inc. (HTLD) announced that the company’s Board of Directors approved a new share repurchase program. Under this program, the company can repurchase up to 5 million shares of outstanding common stock. This program is an addition to the 2.3 million shares previously authorized for repurchase by the Board of Directors. […]

Read more...

Lannett Receives FDA Approval for Dronabinol Capsules

Lannett Company, Inc. (LCI) announced on May 21 that they have received FDA approval for Dronabinol Capsules. The drug is the therapeutic equivalent to Marinol Capsules, and only a handful of suppliers manufacture generic versions of the drug for the US market. Dronabinol Capsules can be used to treat patients with loss of appetite due […]

Read more...

RXi Reports Positive Phase 2 Clinical Trial Results

On May 18, RXi Pharmaceuticals Corporation (RXII) reported positive results from its phase 2 clinical trial of the drug Samcyprone for the treatment of common warts. After weekly application for 10 weeks, participants had a 97.7% positive immunotherapy response rate. 70% of participants experienced a reduction of at least 50% wart size. There is currently […]

Read more...

Atlas Air Worldwide Increases Annual Outlook on Strong First-Quarter Earnings

On May 3, Atlas Air Worldwide Holdings, Inc. (AAWW) announced that the company’s first-quarter volume and revenue increased by 20%. Encouraged by the strong first-quarter financial results, the company increased its annual earnings guidance. Atlas Air Worldwide now expects earnings growth to top 30% during the 2018 fiscal year.   Sonal alerted its subscribers about […]

Read more...